This article critically evaluates the Medicines and Healthcare products Regulatory Agency’s announcement, in March 2008, that GlaxoSmithKline would not face prosecution for deliberately withholding trial data, which revealed not only that Seroxat was ineffective at treating childhood depression but also that it increased the risk of suicidal behaviour in this patient group. The decision not to prosecute followed a four and a half year investigation and was taken on the grounds that the law at the relevant time was insufficiently clear. This article assesses the existence of significant gaps in the duty of candour which had been assumed to exist between drugs companies and the regulator, and reflects upon what this episode tells us about the robustness, or otherwise, of the UK’s regulation of medicines.
Created through collaboration among the Depression and Bipolar Support Alliance (DBSA), University of Michigan Depression Center, and the U.S. National Institute of Mental Health (NIMH).
Weak willpower & procrastination caused by dopamine hypofunction is one of those neurological deficiencies which effort alone can't overcome. Happily, in our transhuman paradise, even the most lethargic spirit can move mountains.
Thanks to AIDS activists it has been legal for several years in the United States to order, for personal use, a 3 month supply of non-Schedule I or II drugs, from overseas. We view International Antiaging Systems (IAS) as a reliable source. We've shared b
A single protein in the brain influences arousal of despair, according to new study in mice. Brain biopsies revealed that mice trying hardest to escape shocks had highest levels of delta-FosB - which may also help humans avoid hopelessness & helplessness.